Guest View
User: Pass: | become a member
Posts Tagged ‘stock’

Green Mountain: Q2′s Dog and Pony Show Reveals More Accounting Fluff

Swallowing pride is a lot harder than sipping a freshly brewed cup of Green Mountain Coffee – 20% hotter today. Here’s a post byJason Merriam on Seeking Alpha, who’s content to "gaze at the big ‘ol Green Mountain from a safe distance." - Ilene

While pride can be hard to swallow at times, panning a stock only to watch its share price skyrocket 20% above and beyond the previous 50% gain we didn’t think possible is downright humiliating. So, congratulations to all Green Mountain Coffee Roasters (GMCR) longs! May the java be with you.

Humble pie aside, investors were clearly impressed by the earnings beat and remainder of 2011 guidance offered by management Tuesday.

We have been bearish on this company for quite awhile and admittedly wrong about the stock since it was at $40 a share.

Yet, we have to hand it to GMCR management for their keen ability to captivate shareholders with such bright optimism while slipping in a secondary offering only minutes within releasing Q2 earnings.

[...]

Again, we have to tip our hat to GMCR management. Now, they have a rich $9 billion market cap, their timing of a secondary, remarkably uncanny. Granted, it’s only about 5% of total current outstanding, but it’s a very shrewd maneuver to build one’s currency (much thanks to bulls). It’s one of the slickest capitalization maneuvers we’ve seen in quite a while.

[...]

If management is so optimistic, why have they sold almost 290,000 shares in the past 12 months?

More here: Green Mountain: Q2′s Dog and Pony Show Reveals More Accounting Fluff – Seeking Alpha.


Tags: , , , , ,




DARK HORSE HEDGE – Super Rad, RDWR

By Scott and Ilene at Dark Horse Hedge – Super Rad, RDWR

All systems go
Soon the world will know
The fury of attack
Feel the wrath of 
The super rad super rad super rad
Su-per Rad!  – Aquabats

Scott came up with this song; it’s hard to believe, but he managed to find a song to fit the post "Super Rad" and I won’t say anything about "Super Bad," I’ll leave that up to you. More from Scott…

We are feeling pretty super about Radware Technology (RDWR) after a 21% surge on Monday to $39.77.  The virtual Dark Horse Hedge (DHH) portfolio bought 100 shares of RDWR on November 11, 2010 at $33.39.  Using Phil’s Buy/Write strategy, DHH sold 1 March 2011 $35 Call for $3.30 and 1 March 2011 Put $5.10, taking in a total of $8.40. 

One strategy at this point would be to sit still and keep the $8.40 option premium, and let the shares be called away at $35 for an additional $1.61 profit (total profit $8.40 plus $1.61 = $10.01)  But at DHH we “feel the wrath of the Super Rad” and would like to potentially enhance our return on RDWR given the suggested buyout price of $47.  Our virtual DHH portfolio will buy back the Mar 2011 $35 Call at the open, Tuesday, December 7, 2010 (at approximately $6.75) and sell the Jan 2012 $35 calls (approximately $9.25).  The added time element will be moot in a buyout as all positions would be settled at the time of acquisition.  The Put should expire worthless in this scenario so there is no need to do anything with it.  There is a rumor that HP may also be interested in acquiring RDWR which could cause a bidding war with Riverbend, if those rumors are indeed true.

Buy (back) RDWR Mar $35 call at the open, Tuesday, December 7, 2010

Sell RDWR Jan 2012 $35 call at the open, Tuesday, December 7, 2010   


Tags: , ,




“Sell the News” Bearish Flattening of Yield Curve Continues; Reflections on “Relative Value”

Continuing on the theme of stock market prices vs. real fundamental value, Mish writes: "This is what happens when investors chase "relative value" instead of asking if there is any real value at all…[This] applies to those chasing the stock market at these lofty levels on the basis ‘stocks are cheap relative to treasuries’ or some other nonsensical reason to justify valuations." – Ilene 

Courtesy of Mish

Curve Watchers Anonymous notes a continuing bearish flattening of the yield curve as shown in the following chart.

click on chart for sharper image

A bearish flattening occurs when the curve tightens with yields generally rising. Conversely, a bullish flattening occurs when the curve tightens with yields generally falling.

Since early November, 5-year treasury yields have risen about 60 basis point, 10-year yields about 45 basis points, and 30-year treasury yields have risen perhaps 5 basis points.

Once again we can see the results in today’s action with thanks to Bloomberg.

Buy the Rumor Sell the News

Note the continued unwind of the "sure-thing" treasury bet, with the Fed concentrating its purchases in the 3-to-7-year range hoping to drive down rates, and everyone front-running the trade. That trade is now unwinding.

Clearly this reaction is not what Bernanke wanted at all.

Reflections on "Relative Value"

Check out that .81 yield on 3-year treasuries. On October 18, investors scarfed up $750 million of 3-year Walmart Bonds yielding .75% for the stupid reason they yielded more than treasuries. Now treasuries are yielding more.

This is what happens when investors chase "relative value" instead of asking if there is any real value at all.

The same idea applies to those chasing the stock market at these lofty levels on the basis "stocks are cheap relative to treasuries" or some other nonsensical reason to justify valuations.

There is no value, only unwarranted bullishness.

Mike "Mish" Shedlock

Originally published at Mish’s Global Economic Trend Analysis, "Sell the News" Bearish Flattening of Yield Curve Continues; Reflections on "Relative Value".


Tags: , , , , , , , , , ,




One More Cup of Coffee Addendum

One More Cup of Coffee Addendum

By Scott Brown at SabrientIlene at Phil’s Stock World, and special thanks to Sam Antar

Last night, we decided to replace the short in JOE, covered yesterday, with a short in GMCR for the DHH virtual portfolio.  We noted:

There are many reasons that insiders may sell shares which have nothing to do with their perception of the company’s prospects or valuation. However, when a week after the last insider sale, the company discloses that the SEC is inquiring into the company’s methods for accounting for revenues, it starts to look more dark and mysterious. It is worth noting that Keurig accounted for over half of GMCR revenue last year, so when the President of Keurig is selling, it is worth a further look. When the SEC discloses an inquiry into the companies accounting it is worth more than a look. Multiple class-action lawsuits have been filed against GMCR since the announcement by the SEC, yet the stock has rebounded from a low of $26.87 to a close today of $31.31.  Rumors of Nestle having interest in GMCR resurfaced on October 12, despite the SEC’s inquiry and pending class-action lawsuits.

To further examine our initial observation, we took a guided tour though the SEC filings, with Sam Antar, who specializes in reviewing SEC filings. The first thing we discovered on the SEC site was that the last date Michelle Stacy exercised 5000 options and then sold the stock for $37 was September 21, 2010.  This transaction was reported in a Form 4 filing on Sept. 23, 2010. 

Next, we looked at the most recent 8K Form filed and we found that the disclosure of the SEC inquiry occurred on September 28, 2010. However, notification of the SEC inquiry occurred eight days earlier, on September 20, 2010: 

On September 20, 2010, the staff of the SEC’s Division of Enforcement informed the Company that it was conducting an inquiry and made a request for a voluntary production of documents and information. Based on the request, the Company believes the focus of the inquiry concerns certain revenue recognition practices and the Company’s relationship with one of its fulfillment vendors. The Company, at the direction of the audit committee of the Company’s board of directors, is cooperating fully with the SEC staff’s inquiry. 

This information…
continue reading


Tags: , , , , , ,




One More Cup of Coffee Addendum

One More Cup of Coffee Addendum

By Scott Brown at SabrientIlene at Phil’s Stock World, and special thanks to Sam Antar

Last night, we decided to replace the short in JOE, covered yesterday, with a short in GMCR for the DHH virtual portfolio.  We noted:

There are many reasons that insiders may sell shares which have nothing to do with their perception of the company’s prospects or valuation. However, when a week after the last insider sale, the company discloses that the SEC is inquiring into the company’s methods for accounting for revenues, it starts to look more dark and mysterious. It is worth noting that Keurig accounted for over half of GMCR revenue last year, so when the President of Keurig is selling, it is worth a further look. When the SEC discloses an inquiry into the companies accounting it is worth more than a look. Multiple class-action lawsuits have been filed against GMCR since the announcement by the SEC, yet the stock has rebounded from a low of $26.87 to a close today of $31.31.  Rumors of Nestle having interest in GMCR resurfaced on October 12, despite the SEC’s inquiry and pending class-action lawsuits.

To further examine our initial observation, we took a guided tour though the SEC filings, with Sam Antar, who specializes in reviewing SEC filings. The first thing we discovered on the SEC site was that the last date Michelle Stacy exercised 5000 options and then sold the stock for $37 was September 21, 2010.  This transaction was reported in a Form 4 filing on Sept. 23, 2010. 

Next, we looked at the most recent 8K Form filed and we found that the disclosure of the SEC inquiry occurred on September 28, 2010. However, notification of the SEC inquiry occurred eight days earlier, on September 20, 2010: 

On September 20, 2010, the staff of the SEC’s Division of Enforcement informed the Company that it was conducting an inquiry and made a request for a voluntary production of documents and information. Based on the request, the Company believes the focus of the inquiry concerns certain revenue recognition practices and the Company’s relationship with one of its fulfillment vendors. The Company, at the direction of the audit committee of the Company’s board of directors, is cooperating fully with the SEC staff’s inquiry. 

This information…
continue reading


Tags: , , , , , ,




DARK HORSE HEDGE

DARK HORSE HEDGE 7-18-10

By Scott at Sabrient and Ilene of PSW

Friday gave us a real-time example of why we use Hysteresis* and confirmations from our technical signals, MACD 12-26-9 and RSI 14-day, to select and monitor the tilt (long-short ratio) of the Dark Horse Hedge’s portfolio.  

The SHORT tilt Friday allowed us to make +1.37% from our 6 SHORT, 3 LONG positions while the S&P 500 gave back -2.88%.  The economic data out Friday of course played a large roll in the failure of our indicators to turn from short to BALANCED.  A sharp decline in the University of Michigan Consumer Index to 65 in July compared poorly with a June figure of 76 and Briefing.com’s estimate of 74.5.  Google’s earnings miss didn’t help either as the S&P 500 fell through its short-term support area to close at 1064.88.  The MACD reading is currently at -3.56 and RSI 14-day at 42.85 (bullish signal is above 50).  The preponderance of evidence heading into the July 19 week is that the market needs to find support in the 1040 range.  

Despite the poor economic data that pushed the market lower on Friday, 19 of 23 S&P 500 companies reporting thus far reported better than projected EPS, and 15 of them beat revenues as well.

Earnings reports will continue to flow in this week.  In our portfolio Western Digital Corp (WDC, long position) reports profits on Tuesday while USG Corp (USG, short position) and Sun Trust Banks Inc (STI, short position) report their losses on July 22.  We will continue to monitor the market action and look for guidance on entering new positions. Key support areas appear to be 1040, 1022 and then 995.

Dark Horse Hedge maintains 10% cash for swing trade opportunities and we are highlighting one for entry on Monday at the Open.

SHORT Terex Corp. (TEX) at the Open Monday.  

TEX will report its latest loss figures on Tuesday, July 21. Twenty analysts project losses ranging from -$.15 to -$.44 with an average of -$.30.  Looking back over the last four quarterly announcements, we see analysts often underestimate Terex’s losses.  For example, in March 2010, analysts estimated -$.52 while the actual loss was $.64. In December 2009, analysts targeted -$.49 and TEX delivered -$.89.  In September 2009, the loss was projected to be $.34 and the company came in at -$.77.  In June 2009, investors were…
continue reading


Tags: , , , , , , , , , , , , , , , , , ,




Something to Love about GSK

Something to Love about GSK

Courtesy of Pharmboy

Visit Pharmboy here for his previous articles on pharm/biotech stocks and chapters in his TA book. 

UK-based GlaxoSmithKline was ranked as the world’s fourth largest player in 2009 (behind US-based Pfizer, France-based Sanofi-Aventis and Switzerland-based Novartis) based on prescription pharma sales. The company was founded in 2000 via the merger of Glaxo Wellcome and SmithKline Beecham and is headquartered in Brentford, London, UK.  I wrote about GSK in my first PSW write-up in 2009.

In terms of its therapeutic focus, GSK owes its market-leading position in the global respiratory market to the Glaxo Laboratories legacy.  Over 30 years ago, Glaxo launched Ventolin for the treatment of asthma and developed and launched Serevent and Flixotide in 1990.  A combination of these two compounds—sold under the brand names Seretide/Advair ($7.8B in 2009).  Similarly, GSK’s origins in the CNS market—currently its third largest therapeutic area of focus—can be traced back to the Wellcome and SmithKline scientists.  Other therapeutic areas of importance include infectious disease and virology (vaccines).


 

The merger of Glaxo Wellcome and SmithKline Beecham created a company with a strong portfolio of blockbuster brands including Seroxat/Paxil (depression),now off patent Seretide/Advair (asthma, COPD) which dominates the respiratory arena, Wellbutrin (depression) now off patent, Augmentin (infections) now off patent, Avandia (diabetes), Imigran/Imitrex (migraine) and Lamictal (epilepsy) now off patent. However, since its creation in 2000, GSK has failed to add to its portfolio with any additional blockbuster drug launches.  Instead, like its rival Pfizer, GSK has been forced to implement cost reductions in the medium term. Sales of Seroxat/Paxil have been eroded by generics (as have Augmentin and Wellbutrin ) in the US market prior to 2011.  In addition, its second largest product Avandia faces declining sales as a result of concerns that have emerged regarding its side-effect profile (e.g., its association with a heightened cardiovascular risk).  Many feel that the company faces pressure from investors to revive its performance. and must turn to M&A activity.  Thusfar, GSK has been reluctant to make such a move. (Gilead for the HIV franchise?) 

What GSK has done instead is sought to in-license product rights in order to boost the sales potential of its portfolio.  Of the eight products launched by GSK since 2000, four have been in-licensed (Lexiva from Vertex, Levitra from Bayer, Boniva from Roche and Vesicare from Astellas). However,


continue reading


Tags: , , , , , , , , , , , ,




Rock Solid Yield: What others are suggesting for Solid Yielding Stocks.

Rock Solid Yield: What others are suggesting for Solid Yielding Stocks.

By Ron Rutherford, courtesy of Sabrient

circa 1955:  Pinnacle Balanced Rock formation in Chiricahua National Monument, Arizona.  (Photo by Josef Muench/Three Lions/Getty Images)

In my last post, I opened the Rock Solid Yield category and briefly introduced you to Sabrient’s upcoming Platinum level subscriber product.  To further define the overall strategy, I will compare and contrast our approach to some worthy suggestions by others.

Perhaps Motley Fool might have some thoughts on the what are the Best Dividend Stocks for Beginners? The question they pose to the round table of contributors and associates is:

I’m just starting, know little, have about $500, and want a solid stock with dividends as my first position. What should I look for?

All the writers provided good suggestions and ideas but the best was provided by Dan Caplinger. For a small first time investor with very limited funds, ETFs could provide diversification and thus lower risks. The Motley Fool, as well as the Rock Solid Yield (”RSY”) portfolio, look for “solid fundamental stocks” which pay dividends for years to come and increase in value over that time. But from the list of stock suggestions, it became obvious that they were not picking stocks strictly based on dividend yield percentages, as most are under 5%, with only BP yielding a generous 9%.   Motley Fool’s advertising even promotes these ideas as 6 Secrets to Finding Dividend “Money Machines”.

6 Secrets of Dividend Investing:
How You Can Earn Great Returns with Less Risk

Finding the best dividend stocks takes some legwork and careful analysis.  However,  here is how you can find the best long-term performers:

1. Avoid the Highest Dividend Stocks — You can’t pick stocks by dividend yield alone.   Above-normal dividends are often a red flag of a company in distress. Studies have consistently shown that you will earn higher long-term returns by avoiding risky stocks with overly high dividends.

All six points made by the panelists are important considerations in making a Rock Solid Yield portfolio but “avoid” might not be the best describer of how to search out the best performing stocks.   I believe a more productive approach is  to be even more cautious and careful about higher paying dividend stocks. The higher the dividend yield,  the greater the scrutiny should be. The risks associated with BP stock from the oil spill are well documented by the media. However,…
continue reading


Tags: , , ,




Did the NY Fed Leave a Funny Taste in YOUR Mouth Too?

Did the NY Fed Leave a Funny Taste in YOUR Mouth Too?

Courtesy of Jr. Deputy Accountant 

A "travesty" LOL.

Reuters:

Federal Reserve Bank directors say a Senate plan to kick bankers off the boards of regional Fed banks is an overreaction to one headline-grabbing incident and could harm the U.S. central bank.

Federal Reserve insiders worry that planned changes to the century-old U.S. central banking system — comprising 12 regional banks and a 7-member Washington-based Board of Governors — would make it more centralized, less independent, and less effective.

A provision in a wide-ranging regulatory reform bill near completion in Washington would ban bankers from serving on the boards of their regulators.

Alarm about possible conflict of interest at the Fed broke out after Goldman Sachs converted to a Fed-regulated bank to withstand the financial crisis.

This put then-New York Fed chairman Stephen Friedman — a Goldman director and former chairman — in violation of the Fed’s rules. Friedman requested a waiver for owning Goldman shares in 2008 and as he waited for the waiver, he bought more shares.

While his actions were not illegal, Friedman stepped down following public furor.

"This legislation, the way it’s proposed, is an overreaction to a particular unique situation, and to have bankers removed from these boards is a travesty," said Mark Hewitt, chief executive of Clear Lake Bank and Trust Co in Iowa and a director at the Federal Reserve Bank of Chicago.

The situation "maybe left a funny taste in someone’s mouth, but that’s not what’s happening in Chicago," he said.

So it isn’t a conflict of interest for Jamie Dimon to sit on the board of his bank’s regulator? Oh please, you’re totally overreacting, who else has their finger on the pulse of banking? Surely not the Fed themselves (as if that’s their job). 

 


Tags: , , ,




The Wheel

The Wheel

Courtesy of Allan

Below is my QQQQ chart, including the Daily Trend Model, an EW count, Auto-Trend Channels and the Elliott Oscillator.

Since the mid-February LONG signal, the index is up about 10%.  Prices have been contained in a well defined trend channel, all the time safely above the Daily Trend Line (navy).  On the bottom oscillator, the recent new highs in price are not being confirmed by new highs in the oscillator.  This suggests that the proposed wave count on the screen is correct and that after the completion of the Wave 5 of 5, a significant decline will be likely.

Below is the same QQQQ chart, less all of the bells and whistles save one, the Daily Trend Model: 

This chart suggests only one thing:  that the market is in an uptrend and traders/investors should be LONG.  The late January EXIT was good for about a 10% decline before the index flipped back to the bullish camp.  There is no suggestion here about any imminent declines,  non-confirmations, wave counts or trend channels.  Just that one thing: LONG.

There may be a market environment coming where such simple, observable, understandable analysis will fail.  Alternatively, this kind of market analysis will continue to be an effective steering current for navigating market direction.  All I can say is that this analysis continues to amaze me with its effectiveness across so many indexes, ETF’s and stocks, as well as across multiple time frames.

I don’t claim to have re-invented the wheel here, only to have found one and am now employing it in all of my market decisions. 

*****

Allan’s new newsletter, “Trend Following Trading Model,” incorporates his chart-based, trend-following method. Most trades last for weeks to months. Allan’s offering PSW readers a special 25% discount. Click here.  For a detailed introduction to the Trend Following Trading Model, read this introductory article.


Tags: , , ,




 

Help One Of Our Own PSW Members

"Hello PSW Members –

This is a non-trading topic, but I wanted to post it during trading hours so as many eyes can see it as possible.  Feel free to contact me directly at jennifersurovy@yahoo.com with any questions.

Last fall there was some discussion on the PSW board regarding setting up a YouCaring donation page for a PSW member, Shadowfax. Since then, we have been looking into ways to help get him additional medical services and to pay down his medical debts.  After following those leads, we are ready to move ahead with the YouCaring site. (Link is posted below.)  Any help you can give will be greatly appreciated; not only to help aid in his medical bill debt, but to also show what a great community this group is.

http://www.youcaring.com/medical-fundraiser/help-get-shadowfax-out-from-the-darkness-of-medical-bills-/126743

Thank you for you time!

 
 

Zero Hedge

Markets Explodes As Bank Of Japan Goes All-In-er; Increases QQE To JPY 80 Trillion

Courtesy of ZeroHedge. View original post here.

Submitted by Tyler Durden.

UPDATE: *NIKKEI 225 EXTENDS ADVANCE TO 5%

NKY is up 1000 points from FOMC

 

 

 

and what do u expect to happen to JGBs when Stocks rip 1000 points... yep they're rallying!

  • Yield on 10-yr govt bond declines 3.5 bps to 0.435%, while 20-yr yield also slides 3.5bps to 1.285%, both lowest since April 2013.
  • 5-yr yield f...


more from Tyler

Phil's Favorites

Looking for a Good Education at a Low Price, Perhaps Free? Head to Europe

Courtesy of Mish.

On June 7, 2014 I wrote Looking to Drastically Reduce College Costs? Study Abroad!

Yesterday, a writer for the Washington Post expressed the same opinion.

Please consider 7 countries where Americans can study at universities, in English, for free (or almost free). Since 1985, U.S. college costs have surged by about 500 percent, and tuition fees keep rising. In Germany, they've done the opposite.

The country's universities have been tuition-free since the beginning of October, when Lower Saxony became the last ...



more from Ilene

Chart School

Moving Averages: Month-End Preview

Courtesy of Doug Short.

Here is a preview of the monthly moving averages I track after the close of the last business day of the month. All three S&P 500 strategies are now signaling "invested" -- unchanged from last month. Two of the five of the Ivy Portfolio ETFs, the PowerShares DB Commodity Index Tracking (DBC and the Vanguard FTSE All-World ex-US ETF (VEU), are signal cash "cash" -- also unchanged from last month.

If a position is less than 2% from a signal, it is highlighted in yellow.


Note: My inclusion of the S&P 500 index updates is intended to illustrate a popular moving moving-average timing strategy. The index signals also give a general sense of how US equities are behaving. Howe...



more from Chart School

All About Trends

Mid-Day Update

Reminder: David is available to chat with Members, comments are found below each post.

Click here for the full report.




To learn more, sign up for David's free newsletter and receive the free report from All About Trends - "How To Outperform 90% Of Wall Street With Just $500 A Week." Tell David PSW sent you. - Ilene...

more from David

Insider Scoop

Jennings Capital Downgrades Ballard Power Systems

Courtesy of Benzinga.

Related BLDP Lake View: Ballard Power Systems 'Making Progress' Morning Market Movers

Jennings Capital downgraded Ballard Power Systems Inc. (NASDAQ: BLDP) in a report issued Thursday from Buy to Hold and lowered its price target from $5 to $3.

Analyst Dev Bhangui noted that the company "reported Q3/14 results that were below our and consensus estimates. EPS were ($0.02) versus JCI and consensus of ($0.01). Revenue and gross margin m...



http://www.insidercow.com/ more from Insider

Sabrient

Sector Detector: Bullish conviction returns, but market likely to consolidate its V-bottom

Courtesy of Sabrient Systems and Gradient Analytics

Bulls showed renewed backbone last week and drew a line in the sand for the bears, buying with gusto into weakness as I suggested they would. After all, this was the buying opportunity they had been waiting for. As if on cue, the start of the World Series launched the rapid market reversal and recovery. However, there is little chance that the rally will go straight up. Volatility is back, and I would look for prices to consolidate at this level before making an attempt to go higher. I still question whether the S&P 500 will ultimately achieve a new high before year end.

In this weekly update, I give my view of the current market environment, offer a technical analysis of the S&P 500 chart, review our weekly fundamentals-based SectorCast rankings of the ten U.S. business sectors, and then o...



more from Sabrient

OpTrader

Swing trading portfolio - week of October 27th, 2014

Reminder: OpTrader is available to chat with Members, comments are found below each post.

 

This post is for all our live virtual trade ideas and daily comments. Please click on "comments" below to follow our live discussion. All of our current  trades are listed in the spreadsheet below, with entry price (1/2 in and All in), and exit prices (1/3 out, 2/3 out, and All out).

We also indicate our stop, which is most of the time the "5 day moving average". All trades, unless indicated, are front-month ATM options. 

Please feel free to participate in the discussion and ask any questions you might have about this virtual portfolio, by clicking on the "comments" link right below.

To learn more about the swing trading virtual portfolio (strategy, performance, FAQ, etc.), please click here ...



more from OpTrader

Stock World Weekly

Stock World Weekly

Newsletter writers are available to chat with Members regarding topics presented in SWW, comments are found below each post.

Here's the latest Stock World Weekly. Enjoy!

(As usual, use your PSW user name and password to sign in. You may also take a free trial.) 

 

#455292918 / gettyimages.com

 

...

more from SWW

Market Shadows

Bill Ackman's Big Pharma Trade Is Making Wall Street A Super Awkward Place

 

#452525522 / gettyimages.com

Intro by Ilene

If you're following Valeant's proposed takeover (or merger) of Allergan and the lawsuit by Allergan against Valeant and notorious hedge fund manager William Ackman, for insider trading this is a must-read article. 

Linette Lopez describes the roles played by key Wall Street hedge fund owners--Jim Chanos, John Paulson, and Mason Morfit, a major shareholder in Valeant. Linette goes through the con...



more from Paul

Option Review

LUV Options Active Ahead Of Earnings

There is lots of action in Southwest Airlines Co. November expiry call options today ahead of the air carrier’s third-quarter earnings report prior to the opening bell on Thursday. Among the large block trades initiated throughout the trading session, there appears to be at least one options market participant establishing a call spread in far out of the money options. It looks like the trader purchased a 4,000-lot Nov 37/39 call spread at a net premium of $0.40 apiece. The trade makes money if shares in Southwest rally 9.0% over the current price of $34.32 to exceed the effective breakeven point at $37.40, with maximum potential profits of $1.60 per contract available in the event that shares jump more than 13% to $39.00 by expiration. In September, the stock tou...



more from Caitlin

Digital Currencies

Goodbye War On Drugs, Hello Libertarian Utopia. Dominic Frisby's Bitcoin: The Future of Money?

Courtesy of John Rubino.

Now that bitcoin has subsided from speculative bubble to functioning currency (see the price chart below), it’s safe for non-speculators to explore the whole “cryptocurrency” thing. So…is bitcoin or one of its growing list of competitors a useful addition to the average person’s array of bank accounts and credit cards — or is it a replacement for most of those things? And how does one make this transition?

With his usual excellent timing, London-based financial writer/actor/stand-up comic Dominic Frisby has just released Bitcoin: The Future of Money? in which he explains all this in terms most readers will have no tr...



more from Bitcoin

Pharmboy

Biotechs & Bubbles

Reminder: Pharmboy is available to chat with Members, comments are found below each post.

Well PSW Subscribers....I am still here, barely.  From my last post a few months ago to now, nothing has changed much, but there are a few bargins out there that as investors, should be put on the watch list (again) and if so desired....buy a small amount.

First, the media is on a tear against biotechs/pharma, ripping companies for their drug prices.  Gilead's HepC drug, Sovaldi, is priced at $84K for the 12-week treatment.  Pundits were screaming bloody murder that it was a total rip off, but when one investigates the other drugs out there, and the consequences of not taking Sovaldi vs. another drug combinations, then things become clearer.  For instance, Olysio (JNJ) is about $66,000 for a 12-week treatment, but is approved for fewer types of patients AND...



more from Pharmboy



FeedTheBull - Top Stock market and Finance Sites



About Phil:

Philip R. Davis is a founder Phil's Stock World, a stock and options trading site that teaches the art of options trading to newcomers and devises advanced strategies for expert traders...

Learn more About Phil >>


As Seen On:




About Ilene:

Ilene is editor and affiliate program coordinator for PSW. She manages the site market shadows, archives, more. Contact Ilene to learn about our affiliate and content sharing programs.

Market Shadows >>